应用蒙特卡洛模拟评价中国成人耐多药结核患者利奈唑胺给药方案  

Evaluation of linezolid dosing regimens in MDR-TB infected patients of China by Monte Carlo simulation

作　　者：邢贞建[1] 李祥[1] 江慧贤 钟洪兰[1] 李昕洁[2] XING Zhenjian;LI Xiang;JIANG Huixian;ZHONG Honglan;LI Xinjie(Department of Pharmacy,Guanghzou Chest Hospital,Guangzhou 510095,China;不详)

机构地区：[1]广州市胸科医院药剂科,广州510095 [2]广州市胸科医院内科,广州510095 [3]广东省食品药品职业技术学校,广州510663

出　　处：《实用医学杂志》2020年第16期2216-2219,共4页The Journal of Practical Medicine

摘　　要：目的评价利奈唑胺治疗耐多药结核时不同给药方案的疗效。方法将利奈唑胺1200、600和300 mg/d的给药方案进行5000次蒙特卡洛模拟,对得到的不同达标概率(PTA)和对靶值的累积反应分数(CRF)进行比较,评价各方案可能达到的疗效。结果对耐药结核菌(MDR-TB)和泛耐药结核菌(XDR-TB)利奈唑胺在1200 mg/d的累积反应分数(CFR)为95.09%和91.88%,在600 mg/d的CFR为90.98%和86.37%,在300 mg/d的CRF为67.65%和73.85%。结论利奈唑胺在1200 mg/d的给药方案对MDR-TB和XDR-TB取得良好效果的概率高,但600、300 mg/d的给药方案对高MIC菌株感染时取得良好效果的概率降低。Objective The research aimed to evaluate the therapeutic effects of different regimens of linezolid for the treatment of MDR-TB.Methods 5000 times of Monte Carlo simulations were conducted.to estimate the probability of target attainment(PTA)and cumulative fraction of response(CRF)for linezolid at 1200 mg/d,600 mg/d and 300 mg/d.Result For MDR-TB and XDR-TB,the estimated C.FRs were 95.09%and 91.88%at1200 mg/d,90.98%and 86.37%at 600 mg/d,67.65%and 73.85%at 300 mg/d.Conclusion There may be a greater therapeutic effect at 1200 mg/d but lower at 600 mg/d and 300 mg/d for Linezolid in the treatment of MDRTB and XDR-TB.

关 键 词：蒙特卡洛模拟 利奈唑胺 耐多药结核 

分 类 号：R969.3[医药卫生—药理学]